Cycling across Canada to cure DMD
What’s it like to live with DMD? As a parent, to face the reality that your child has a fatal disease? As a person with DMD, to face an inevitable, premature death in your twenties? As a sibling, [...]
Positive data about utrophin modulator
Today, Summit Therapeutics announced positive 24-week interim data from PhaseOut DMD (Phase 2 clinical trial of the utrophin modulator ezutromid). This data showed a significant reduction in [...]
Portait of Duchenne – repurposing existing drugs for DMD
Steve J. Winder, PhD Professor of Molecular Cell Biology, Director of Postgraduate Teaching, Director of External Relations, Department of Biomedical Science, The University of Sheffield, United [...]
Portait of Duchenne – Edasalonexent: The potential to modify DMD
Joanne M. Donovan, MD, PhD Chief Medical Officer at Catabasis Pharmaceuticals, Cambridge, Massachusetts, USA In this fifth interview of our series “Portrait of Duchenne,” La Force DMD talks with [...]
Portrait of Duchenne – Ataluren a promising treatment for DMD
Ellen Welch, PhD Group leader biology at PTC Therapeutics, South Plainfield, New Jersey, USA In this fourth interview of our series “Portrait of Duchenne”, La Force DMD talks with Ellen [...]
Portrait of Duchenne – Utrophin Modulator
Michelle Avery, PhD Director, Investor Relations at Summit Therapeutics plc In this second interview of our series “Portrait of Duchenne,” La Fondation La Force talks with Michelle Avery, the [...]
Utrophin production might be a good option for people with DMD
Utrophin could potentially replace dystrophin. In people with Duchenne muscular dystrophy (DMD), dystrophin does not function properly. Numerous media outlets have recently reported many exciting [...]
New treatments for Duchenne muscular dystrophy: a stalled process
Initial Duchenne muscular dystrophy diagnoses usually come about around age 4 or 5 years, mostly in young boys. Duchenne muscular dystrophy often referred to as “DMD”, is the most severe form of [...]
